D-Dimer is not present in plasma as it is only found in the blood after a blood clot is degraded. Therefore, D-Dimer is not naturally present in plasma unless the coagulation system has been activated, and it is commonly measured in serum only. In the plasma samples tested in-house, all samples were detectable but at the same concentration, so the data isn't reliable with plasma samples. The kit works well with serum samples, with normal ranges of 142 – 5146 ng/mL and a median of 433 ng/mL.
HCVD2MAG-67K
MILLIPLEX® Human Cardiovascular Disease Panel
Configurable Human CVD 10-Plex Panel 2
Synonym(s):
CVD assay snapshot, CVD multiplex product sheet, cardiovascular biomarker listing, cardiovascular biomarker profile, coagulation and inflammation detection kit, human CVD assay overview, human cardiovascular panel summary, human cardiovascular research tool, human vascular biomarker info, vascular inflammation biomarker panel
Sign In to View Organizational & Contract Pricing.
About This Item
UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000
To order a Milliplex® kit, please search for your analyte of interest.
Product Name
MILLIPLEX® Human Cardiovascular Disease Panel,
Quality Level
description
Configurable Human CVD 10-Plex Panel 2
species reactivity
human
packaging
pkg of 1 ea
manufacturer/tradename
Milliplex®
assay range
inter-assay cv: <20%
intra-assay cv: <15%, accuracy: 88%
(Myoglobin), accuracy: 90%
(P-selectin), accuracy: 98%
(GDF-15), standard curve range: 0.0005-2.5 ng/mL
(GDF-15), standard curve range: 0.012-50 ng/mL
(Lipocalcin-2/NGAL), standard curve range: 0.024-100 ng/mL
(Myoglobin & MPO), standard curve range: 0.085-350 ng/mL
(sICAM-1), standard curve range: 0.122-500 ng/mL
(sVCAM-1), standard curve range: 0.244-1,000 ng/mL
(D-dimer, SAA & P-selectin), standard curve range: 1.221-5,000 ng/mL
(ADAMTS 13)
technique(s)
multiplexing: suitable
input
plasma
cell culture supernatant(s)
detection method
fluorometric (Luminex® xMAP® technology)
shipped in
wet ice
storage temp.
2-8°C
General description
Cardiovascular disease is closely linked to inflammation, endothelial dysfunction, oxidative stress, and coagulation abnormalities. This set of biomarkers—ADAMTS13, D-dimer S, GDF15, sICAM-1, Myeloperoxidase (MPO), Myoglobin, NGAL/Lipocalin-2, sP-Selectin, Serum Amyloid A, and sVCAM-1—captures key indicators of vascular injury, immune activation, and thrombotic risk. These analytes are widely studied in the context of atherosclerosis, acute coronary syndromes, and systemic inflammation, making them highly relevant for translational and clinical cardiovascular research.
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 10 analytes in human serum, plasma, or cell culture supernatants.
Analytes included: ADAMTS13, D-dimer S, GDF15, sICAM-1, Myeloperoxidase (MPO), Myoglobin, NGAL/Lipocalin-2, sP-Selectin, Serum Amyloid A, sVCAM-1Note: D-Dimer cannot be measured in plasma samples.
Assay Characteristics: Refer to assay protocol for details on cross-reactivity, sensitivity, precision, and accuracy.
Analytes included: ADAMTS13, D-dimer S, GDF15, sICAM-1, Myeloperoxidase (MPO), Myoglobin, NGAL/Lipocalin-2, sP-Selectin, Serum Amyloid A, sVCAM-1Note: D-Dimer cannot be measured in plasma samples.
Assay Characteristics: Refer to assay protocol for details on cross-reactivity, sensitivity, precision, and accuracy.
Features and Benefits
Features:
- Targets biomarkers involved in vascular inflammation, endothelial activation, and coagulation
- Includes 10 analytes relevant to cardiovascular risk, oxidative stress, and immune response
- Multiplex format enables simultaneous detection from minimal sample volume
- Compatible with human serum and plasma samples
- Designed for research in atherosclerosis, thrombosis, acute coronary syndromes, and systemic inflammation
- Provides a comprehensive profile of cardiovascular and inflammatory biomarkers
- Supports investigation of vascular injury, immune activation, and thrombotic mechanisms
- Facilitates evaluation of therapeutic interventions and biomarker-based risk assessment
- Enables high-throughput analysis with reduced sample and reagent use
- Delivers reproducible, sensitive results for translational and clinical research
Legal Information
Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
For research use only. Not for use in diagnostic procedures.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
1 of 1
This Item | |||
|---|---|---|---|
| species reactivity human | species reactivity human | species reactivity human | species reactivity human |
| assay range accuracy: 88% | assay range accuracy: 100% | assay range accuracy: 92% | assay range accuracy: 102% |
| manufacturer/tradename Milliplex® | manufacturer/tradename Milliplex® | manufacturer/tradename Milliplex® | manufacturer/tradename Milliplex® |
| Quality Level 200 | Quality Level 200 | Quality Level 200 | Quality Level 200 |
| detection method fluorometric (Luminex® xMAP® technology) | detection method fluorometric (Luminex® xMAP® technology) | detection method fluorometric (Luminex® xMAP® technology) | detection method fluorometric (Luminex® xMAP® technology) |
| shipped in wet ice | shipped in wet ice | shipped in wet ice | shipped in wet ice |
Still not finding the right product?
Explore all of our products under MILLIPLEX® Human Cardiovascular Disease Panel
signalword
Warning
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
Storage Class
10 - Combustible liquids
wgk
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Uncover tips and tricks to multiplexing in this guide from the experts. Learn how you can enhance the power of your research with MILLIPLEX® multiplexing, including industry guidance for immunoassays, multiplexing tips, one-day MILLIPLEX® multiplex assays for limited lab time, and more.
Learn about biomarkers of cardiovascular disease (CVD) and discover how multiplex CVD panels, such as MILLIPLEX® multiplex assays, are being used to increase the efficiency of biomarker discovery for CVD research.
Estefania Simoes et al.
International journal of obesity (2005), 45(4), 879-887 (2021-02-03)
Childhood overweight and obesity are a global concern, with prevalence rising dramatically over the last decades. The condition is caused by an increase in energy intake and reduction of physical activity, leading to excessive fat accumulation, followed by systemic chronic
Alberto Soriano-Maldonado et al.
Journal of clinical medicine, 7(12) (2018-11-28)
This study assessed the effect of 12-week aerobic exercise on arterial stiffness (primary outcome), inflammation, oxidative stress, and cardiorespiratory fitness (secondary outcomes) in women with systemic lupus erythematosus (SLE). In a non-randomized clinical trial, 58 women with SLE were assigned
Lilliam Rocha-Penha et al.
Hypertension (Dallas, Tex. : 1979), 69(6), 1173-1180 (2017-05-04)
Elevated levels of myeloperoxidase have been demonstrated in women with preeclampsia where it may contribute to endothelial dysfunction mediated, in part, by nitric oxide impairment. In this study, we investigated myeloperoxidase in hypertensive disorders of pregnancy and its contribution to
Global Trade Item Number
| SKU | GTIN |
|---|---|
| HCVD2MAG-67K | 04053252987267 |
-
Can you provide more information about the statement in the Human CVD 2 Milliplex kit (HCVD2MAG-67K) that specifically mentions D-Dimer should be measured in serum, not plasma?
1 answer-
Helpful?
-
-
Are the SAA beads in the Human CVD Panel 2 kit designed to target SAA-1?
1 answer-
The capture antibody will detect SAA1 and SAA2. The detection will also detect SAA1 but does not detect SAA2. Neither antibody has been tested against SAA3 or SAA4.
Helpful?
-